CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
Feb 6, 2023 → Jul 31, 2023
NCT ID
NCT05725434About CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab)
CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab) is a phase 3 stage product being developed by Celltrion for Rheumatoid Arthritis. The current trial status is unknown. This product is registered under clinical trial identifier NCT05725434. Target conditions include Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05725434 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Rheumatoid Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tilmanocept | Navidea Biopharmaceuticals | Phase 1 | 25 |
| Tc99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 44 |
| KPL-404 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid | Eli Lilly | Phase 3 | 77 |
| LY2127399 | Eli Lilly | Phase 3 | 77 |
| Baricitinib + TNF Inhibitor | Eli Lilly | Approved | 85 |
| CT-P17 SC AI (adalimumab) | Celltrion | Phase 3 | 77 |
| Remsima IV + Remsima SC | Celltrion | Pre-clinical | 23 |
| CT-P13 + Remicade | Celltrion | Phase 3 | 77 |
| CT-P47 + EU-approved RoActemra | Celltrion | Phase 3 | 77 |
| Infliximab | Celltrion | Phase 3 | 77 |
| CT-P13 SC Auto-Injector + Placebo Auto-Injector | Celltrion | Phase 3 | 77 |
| Rituximab, MTX, folic acid | Celltrion | Phase 1 | 33 |
| CT-P10 + Rituxan + MabThera | Celltrion | Phase 3 | 77 |
| CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 | Celltrion | Phase 3 | 77 |
| rituximab | Celltrion | Phase 1 | 33 |
| CT-P17 SC + Humira SC | Celltrion | Phase 3 | 77 |
| Adalimumab | Celltrion | Pre-clinical | 23 |
| Infliximab | Celltrion | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Pre-clinical | 23 |
Other Products from Celltrion
Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85